Drug intelligence / Profile preview

CGX-195

Development stage: Preclinical
Lead developer: Congruence Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

CGX-195 is an oral small-molecule pharmacological corrector designed to treat alpha-1 antitrypsin deficiency (AATD). Developed by Congruence Therapeutics using its proprietary Revenir computational drug discovery platform, CGX-195 targets mutant alpha-1 antitrypsin (A1AT, encoded by the SERPINA1 gene), specifically stabilizing the misfolded Z-AAT protein. By preventing its polymerization and accumulation in hepatocytes, CGX-195 aims to mitigate liver fibrosis while simultaneously increasing the secretion of functional A1AT into the plasma to protect against lung emphysema.

Targets

SERPINA1 Z (Alpha-1-antitrypsin Z variant protein)

Beyond the preview

Go deeper on CGX-195.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CGX-195.

Explore the full profile